Skip to main content
. 2019 Nov 29;25(3):e598–e601. doi: 10.1634/theoncologist.2019-0523

Figure 1.

Figure 1

Time from marketing authorization to reimbursement of novel drugs for non‐small cell lung cancer in 10 Central and Eastern European countries. Data are expressed as percentage of drugs available in particular timeframe. Abbreviations: AUT, Austria; BLG, Bulgaria; CRO, Croatia; CZR, Czech Republic; HUN, Hungary; POL, Poland; ROM, Romania; SLK, Slovakia; SLO, Slovenia; SRB, Serbia.